Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms, Plasma Cell 2Lymphoma 2Immunoglobulin Light-chain Amyloidosis 2Triple Negative Breast Neoplasms 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Paraproteinemias 1Neoplasms 1Neoplasm, Residual 1Malignant Plasma Cell Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lung Neoplasms 1Leukemia, Plasma Cell 1Leukemia 1Hematologic Diseases 1Esophageal Stenosis 1Esophageal Neoplasms 1Corneal Diseases 1Breast Cancer Patients Treated With T-DXd 1Brain Neoplasms 1Blood Protein Disorders 1Ann Arbor Stage II Mantle Cell Lymphoma 1Amyloidosis 1

Interventions

pomalidomide 1Lenalidomide 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Malignant Plasma Cell Neoplasms × Dexamethasone × Clear all
NCT07560449 2026-05-01

QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms

Qilu Pharmaceutical Co., Ltd.

Phase 2 Not yet recruiting
162 enrolled
Plasma cell

Malignant Plasma Cell Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡